
Medtronic plc
NYSE•MDT
CEO: Mr. Geoffrey Straub Martha
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1973-05-02
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
Contact Information
Market Cap
$128.09B
P/E (TTM)
26.9
36.3
Dividend Yield
2.8%
52W High
$106.33
52W Low
$79.29
52W Range
Rank31Top 15.1%
5.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q2 2026 Data
Revenue
$8.96B+6.64%
4-Quarter Trend
EPS
$1.07+8.08%
4-Quarter Trend
FCF
$457.00M-17.51%
4-Quarter Trend
2026 Q2 Earnings Highlights
Key Highlights
Net Sales Increased 8% Six-month net sales reached $17.54B USD, showing an 8% increase driven by strong performance across most businesses.
Diluted EPS Grew 8.1% Quarterly diluted EPS was $1.07 USD, up 8.1% from $0.99 USD, aided by sales growth and tax benefit realization.
Operating Cash Flow Rises Six-month operating cash flow provided $2.01B USD, reflecting a $0.1B increase due to higher customer cash collections.
Cardiovascular Segment Strong Cardiovascular net sales grew 10% for the six months, reaching $6.72B USD, fueled by Cardiac Ablation Solutions and TAVR growth.
Risk Factors
Macroeconomic Headwinds Persist Business faces risks from competitive pricing, inflation, supply chain issues, and evolving international trade policy impacts globally.
Diabetes Separation Execution Intent to separate the Diabetes business unit, expected completion within 18 months, introduces execution and transition risks.
Unrecognized Tax Benefit Exposure Gross unrecognized tax benefits total $2.9B USD; recognition could materially impact future consolidated earnings and effective tax rate.
Litigation Uncertainty Remains Ongoing legal matters, including environmental and product liability claims, carry potential material adverse impact on financial results.
Outlook
Diabetes Business Separation Management intends to complete the separation of the Diabetes Operating Unit into a new independent public company within 18 months.
Focus on Product Pipeline Expect continued growth from key product launches like Micra pacing and adoption of the Hugo robotic-assisted surgery system.
Managing Tariff Impacts Estimate pre-tax net tariff impact of $185M USD in fiscal year 2026; proactive mitigation steps are currently being taken.
Debt Management Strategy Total debt stands at $29.1B USD; focus remains on utilizing unsecured senior debt and managing foreign currency exposure.
Peer Comparison
Revenue (TTM)
CVS$394.08B
MCK$387.09B
HCA$74.37B
Gross Margin (Latest Quarter)
VRTX86.5%
77.9%
PFE74.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| DHR | $162.44B | 46.0 | 6.9% | 21.1% |
| PFE | $146.95B | 15.0 | 10.9% | 29.6% |
| BSX | $137.21B | 49.2 | 12.8% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.6%
Moderate Growth
4Q Net Income CAGR
2.0%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 17, 2026
EPS:$1.34
|Revenue:$8.89B
Reports
All Years
Form 10-Q - Q2 2026
Period End: Oct 24, 2025|Filed: Nov 25, 2025|Revenue: $8.96B+6.6%|EPS: $1.07+8.1%MissForm 10-Q - Q1 2026
Period End: Jul 25, 2025|Filed: Aug 26, 2025|Revenue: $8.58B+8.4%|EPS: $0.81+0.0%MissForm 10-K - FY 2025
Period End: Apr 25, 2025|Filed: Jun 20, 2025|Revenue: $33.54B+3.6%|EPS: $3.63+31.0%BeatForm 10-Q - Q3 2025
Period End: Jan 24, 2025|Filed: Feb 25, 2025|Revenue: $8.29B+2.5%|EPS: $1.01+2.0%MissForm 10-Q - Q2 2025
Period End: Oct 25, 2024|Filed: Nov 26, 2024|Revenue: $8.40B+5.2%|EPS: $0.99+45.6%MissForm 10-Q - Q1 2025
Period End: Jul 26, 2024|Filed: Aug 27, 2024|Revenue: $7.92B+2.8%|EPS: $0.81+37.3%MissForm 10-K - FY 2024
Period End: Apr 26, 2024|Filed: Jun 20, 2024|Revenue: $32.36B+3.6%|EPS: $2.77-2.1%BeatForm 10-Q - Q3 2024
Period End: Jan 26, 2024|Filed: Feb 27, 2024|Revenue: $8.09B+4.7%|EPS: $0.99+7.6%Miss